Latest Kynam Capital Management, LP Stock Portfolio

Kynam Capital Management, LP Performance:

2025 Q4: 38.25%YTD: 37.48%2024: 24.69%

Performance for 2025 Q4 is 38.25%, and YTD is 37.48%, and 2024 is 24.69%.

About Kynam Capital Management, LP and 13F Hedge Fund Stock Holdings

On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Kynam Capital Management, LP reported an equity portfolio of $1.6 Billions as of 31 Dec, 2025.

The top stock holdings of Kynam Capital Management, LP are COGT, VERA, SNDX. The fund has invested 14% of it's portfolio in COGENT BIOSCIENCES INC and 11.1% of portfolio in VERA THERAPEUTICS INC.

The fund managers got completely rid off UNITED THERAPEUTICS CORP DEL (UTHR), IRONWOOD PHARMACEUTICALS INC (IRWD) and UROGEN PHARMA LTD (URGN) stocks. They significantly reduced their stock positions in ENGENE HOLDINGS INC, VIRIDIAN THERAPEUTICS INC (VRDN) and WAVE LIFE SCIENCES LTD (WVE). Kynam Capital Management, LP opened new stock positions in BIOHAVEN LTD, SUTRO BIOPHARMA INC (STRO) and ALECTOR INC (ALEC). The fund showed a lot of confidence in some stocks as they added substantially to KALVISTA PHARMACEUTICALS INC (KALV), CYTOMX THERAPEUTICS INC (CTMX) and CULLINAN THERAPEUTICS INC (CGEM).

Kynam Capital Management, LP Annual Return Estimates Vs S&P 500

Our best estimate is that Kynam Capital Management, LP made a return of 38.25% in the last quarter. In trailing 12 months, it's portfolio return was 37.48%.

Performance
S&P 500

New Buys

Ticker	$ Bought
biohaven ltd	7,935,560
sutro biopharma inc	5,548,860
evommune inc	3,175,450
alector inc	3,120,000
prelude therapeutics inc	2,287,710

New stocks bought by Kynam Capital Management, LP

Additions

Ticker	% Inc.
kalvista pharmaceuticals inc	198
cytomx therapeutics inc	145
cullinan therapeutics inc	35.27
apellis pharmaceuticals inc	12.37

Additions to existing portfolio by Kynam Capital Management, LP

Reductions

Ticker	% Reduced
engene holdings inc	-70.11
viridian therapeutics inc	-66.79
mbx biosciences inc	-53.26
cg oncology inc	-52.83
wave life sciences ltd	-52.43
relay therapeutics inc	-50.67
travere therapeutics inc	-45.47
dynavax technologies corp	-35.88

Kynam Capital Management, LP reduced stake in above stock

Sold off

Ticker	$ Sold
ironwood pharmaceuticals inc	-7,161,540
sutro biopharma inc	-4,418,500
urogen pharma ltd	-6,935,710
edgewise therapeutics inc	-4,119,540
united therapeutics corp del	-20,009,800

Kynam Capital Management, LP got rid off the above stocks

Sector Distribution

Kynam Capital Management, LP has about 89.3% of it's holdings in Healthcare sector.

Sector	%
Healthcare	89.3
Others	10.7

Market Cap. Distribution

Kynam Capital Management, LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
MID-CAP	47.3
SMALL-CAP	40.8
UNALLOCATED	10.7
MICRO-CAP	1.2

Stocks belong to which Index?

About 84.7% of the stocks held by Kynam Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	84.7
Others	15.3

Top 5 Winners (%)		%
BNR	burning rock biotech ltd	132.9 %
COGT	cogent biosciences inc	131.3 %
NRIX	nurix therapeutics inc	100.5 %
ELYM	climb bio inc	99.0 %
WVE	wave life sciences ltd	97.6 %

Top 5 Winners ($)		$
COGT	cogent biosciences inc	148.7 M
VERA	vera therapeutics inc	80.5 M
SNDX	syndax pharmaceuticals inc	46.6 M
WVE	wave life sciences ltd	32.6 M
PCVX	vaxcyte inc	30.3 M

Top 5 Losers (%)		%
CRBU	caribou biosciences inc	-28.8 %
AMRN	amarin corp plc	-12.4 %
PRQR	proqr thrapeutics n v	-5.0 %
IMCR	immunocore hldgs plc	-4.1 %
GERN	geron corp	-3.6 %

Top 5 Losers ($)		$
CRBU	caribou biosciences inc	-2.1 M
IMCR	immunocore hldgs plc	-1.5 M
AMRN	amarin corp plc	-1.2 M
PRQR	proqr thrapeutics n v	-0.2 M
GERN	geron corp	-0.2 M

Kynam Capital Management, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Kynam Capital Management, LP

Kynam Capital Management, LP has 35 stocks in it's portfolio. About 71.9% of the portfolio is in top 10 stocks. CRBU proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for Kynam Capital Management, LP last quarter.

Last Reported on: 17 Feb, 2026

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
ALEC	alector inc	0.20	2,000,000	3,120,000	new

AMRN	amarin corp plc	0.35	389,273	5,432,300	reduced	-32.43

APLS	apellis pharmaceuticals inc	1.46	908,607	22,824,200	added	12.37

BCRX	biocryst pharmaceuticals inc	4.67	9,366,530	73,058,900	reduced	-0.25

BEAM	beam therapeutics inc	4.32	2,440,210	67,642,700	reduced	-3.08

BNR	burning rock biotech ltd	1.28	994,883	20,046,900	unchanged	0.00

CGEM	cullinan therapeutics inc	2.06	3,114,130	32,231,300	added	35.27

CLDX	celldex therapeutics inc new	10.31	5,943,180	161,417,000	reduced	-2.58

COGT	cogent biosciences inc	13.99	6,165,220	218,989,000	reduced	-21.82

CRBU	caribou biosciences inc	0.25	2,503,300	3,980,250	reduced	-18.4

CTMX	cytomx therapeutics inc	2.44	8,966,080	38,195,500	added	145

DSGN	design therapeutics inc	0.47	784,606	7,359,600	reduced	-23.79

DVAX	dynavax technologies corp	1.35	1,375,630	21,157,200	reduced	-35.88

ELYM	climb bio inc	0.26	1,028,340	4,113,360	unchanged	0.00

EWTX	edgewise therapeutics inc	0.00	0.00	0.00	sold off	-100

GERN	geron corp	0.29	3,456,320	4,562,340	unchanged	0.00

IMCR	immunocore hldgs plc	1.90	856,462	29,727,800	reduced	-15.14

IRWD	ironwood pharmaceuticals inc	0.00	0.00	0.00	sold off	-100

KALV	kalvista pharmaceuticals inc	1.87	1,810,950	29,246,900	added	198

NRIX	nurix therapeutics inc	2.39	1,970,360	37,377,700	reduced	-9.14